查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2067718

美國CLIA內分泌檢測市場規模、佔有率和趨勢分析報告：按產品類型、檢測類型、臨床環境和細分市場預測（2026-2033年）

U.S. CLIA Endocrine Testing Market Size, Share & Trends Analysis Report By Product (Kits & Reagents, Instruments), By Testing Type, By Clinical Setting (OBGYN Office, Fertility / IVF Clinics), And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國CLIA內分泌檢測市場概覽

美國 CLIA 內分泌檢測市場預計到 2025 年價值 140.6 億美元，預計到 2033 年將達到 343.8 億美元，2026 年至 2033 年的複合年成長率為 11.94%。

市場成長的促進因素是慢性疾病和荷爾蒙相關疾病的日益普遍，以及對荷爾蒙檢測更高的敏感度和分析準確性的需求。

自動化CLIA平台技術的進步提高了診斷效率。此外，遵守《臨床實驗室改進法案》（CLIA）可確保檢測品質的標準化，從而促進美國內分泌檢測服務的統一部署。

慢性疾病和荷爾蒙相關疾病負擔的日益加重，正推動美國對內分泌檢測的需求顯著成長。糖尿病、甲狀腺功能障礙和卵巢症候群（PCOS）等疾病的盛行率因人口老化、缺乏運動、肥胖和環境因素等因素而不斷上升。世界衛生組織（WHO）於2026年1月發布的報告指出，全球約有10-13%的育齡女性患有PCOS，其中近70%的病例未被確診，凸顯了診斷檢測方面的巨大缺口。此外，美國國家生物技術資訊中心（NCBI）報告稱，美國至少有5%的成年人患有甲狀腺機能低下症、骨質疏鬆和維生素D缺乏等內分泌疾病。這種日益成長的臨床負擔正推動著美國各地CLIA認證實驗室對高靈敏度內分泌檢測的需求持續成長。

美國自動化化學冷光免疫檢測(CLIA) 平台的進步顯著提高了內分泌檢測的效率、可擴展性和準確性。最新的 CLIA 分析儀專為高通量處理、最大限度減少人工干預和快速結果報告而設計，使檢查室能夠在處理大量檢測的同時減少操作誤差。這些系統支援自動化檢體處理、校準和結果解讀，從而提高了荷爾蒙分析的可重複性和一致性。例如，2026 年 3 月，羅氏公司 (F. Hoffmann-La Roche) 的 Ionify 類固醇檢測法與 cobas 質譜儀解決方案整合後，獲得了美國食品藥物管理局(FDA) 頒發的 CLIA 中等複雜程度認證。這使得普通臨床檢查室能夠透過自動化和標準化的工作流程進行高精度的類固醇激素檢測。這些進步正在加速美國 CLIA 認證檢查室採用高通量自動化內分泌檢測解決方案，從而提高診斷效率和可擴展性。

遵守《臨床實驗室改進法案》(CLIA) 的規定，透過確保各檢查室檢測品質、準確性和可靠性的標準化，推動了美國 CLIA 內分泌檢測行業的成長。這些規定強制要求嚴格的品管、能力測試和人員配備標準，從而減少診斷錯誤，並提高荷爾蒙檢測結果的臨床可靠性。按檢測複雜度進行分類，使實驗室能夠在保持合規性的同時擴展服務範圍。這個系統化的框架促進了高度自動化檢測平台的應用，提高了診斷實踐的一致性，並最終增加了檢測量，從而支持了美國內分泌檢測服務的持續發展。

大規模參考實驗室的成長，加上有利的報銷機制和保險覆蓋範圍，正在推動美國CLIA內分泌檢測市場的擴張。領先的診斷實驗室正在提升檢測能力並實施自動化，以實現集中式檢測模式，從而提高處理能力並加快結果交付速度。這提高了營運效率，並支援大規模內分泌檢測。同時，美國的報銷政策透過提高成本效益和便利性，促進了診斷服務的使用。儘管價格壓力依然存在，但穩定的保險覆蓋範圍繼續支撐著檢測需求，並有助於市場的穩定成長。

目錄

第1章：美國CLIA內分泌檢測市場：調查方法與範圍

第2章：美國CLIA內分泌檢測市場：執行摘要

  • 市場概覽
  • 產品概述
  • 測試類型概述
  • 臨床試驗中心概覽
  • 競爭格局概述

第3章：美國CLIA內分泌檢測市場：變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場譜系展望
  • 市場動態
  • 市場動態分析
  • 市場限制因素分析
  • 波特五力分析
  • PESTEL 分析
  • 管道分析

第4章：美國CLIA內分泌檢測市場：基於產品的估算與趨勢分析

  • 美國CLIA內分泌檢測市場：產品特定儀錶板
  • 美國CLIA內分泌檢測市場：基於產品的波動分析
  • 美國CLIA內分泌檢測市場：依產品及銷售收入分類
  • 試劑盒和試劑
  • 裝置

第5章：美國CLIA內分泌檢測市場：依檢測類型、價值及數量（檢測次數）分類（2021-2033年）

  • 2021年至2033年甲狀腺檢測市場估算與預測
    • 2021年至2033年TSH市場估算與預測
    • 游離4碘甲狀腺素(fT4) 市場估算與預測（2021-2033 年）
    • T4（總合）市場估算與預測（2021-2033）
    • 游離三碘甲狀腺素（FT3）市場估算與預測（2021-2033 年）
    • T3（總合）市場估算與預測（2021-2033）
    • 2021年至2033年抗TPO抗體市場估算與預測
    • 2021年至2033年抗Tg檢測市場估算與預測
    • 2021年至2033年甲狀腺球蛋白（Tg）市場估算與預測
    • 2021年至2033年T3樹脂摻入測試市場估算與預測
  • 2021年至2033年荷爾蒙檢測市場估算與預測
    • 2021-2033年FSH市場估算與預測
    • hCG市場估計與預測（2021-2033）
    • 2021年至2033年睪固酮市場估算與預測
    • 2021年至2033年孕酮市場估算與預測
    • 2021-2033年催乳素市場規模估算與預測
    • 2021年至2033年雌二醇（E2）市場估算與預測
    • 黃體激素(LH) 市場估計與預測 (2021-2033)
    • 性荷爾蒙結合球蛋白 (SHBG) 市場估算與預測 (2021-2033)
    • DHEA-S（硫酸脫氫表雄酮）市場估算與預測（2021-2033 年）
    • 人體生長荷爾蒙（HGH）市場估算與預測（2021-2033）
    • 抗穆氏管荷爾蒙（AMH）市場估算與預測（2021-2033）
  • 骨骼健康市場估計與預測（2021-2033）
    • 2021年至2033年維生素D市場估算與預測
    • 副甲狀腺素（PTH）市場規模估算與預測（2021-2033）
    • 血清CTX（羧基末端膠原蛋白交聯）市場估算與預測（2021-2033年）
    • NTx（N-端肽）市場估算與預測（2021-2033）
    • 2021年至2033年骨鈣素市場估算與預測
    • 鹼性磷酸酶 (ALP) 市場估計與預測 (2021-2033)

第6章：美國CLIA內分泌檢測市場：依檢測類型和臨床應用、價值和數量（檢測次數）分類（2021-2033年）

  • 美國CLIA內分泌檢測市場：按檢測類型、價值和檢測數量分類的儀錶板（檢測數量）
  • 美國CLIA內分泌檢測市場：依檢測類型、價值和檢測數量（檢測數量）分析波動情況
  • 美國CLIA內分泌檢測市場：依檢測類型、價值和檢測數量分類
  • 婦產科診所
    • 婦產科診所市場估算與預測（2021-2033 年）（檢查次數）
  • 臨床檢查室（POL）
    • 臨床檢查室（POL）市場估算與預測（2021-2033 年）（檢測數量）
  • 小規模醫院檢查室（100床或以下）
    • 中型醫院檢查室（100 張病床或以下）的市場估算與預測（2021-2033 年）（檢測數量）
  • 中型醫院（100-500床）的檢查室
    • 中型醫院檢查室（100-500 床）市場估算與預測（2021-2033 年）（檢測次數）
  • 大型醫院檢查室（500床或以上）
    • 大型醫院檢查室（100-500 床）的市場估算與預測（2021-2033 年）（檢測數量）

第7章 競爭情勢

  • 主要市場參與企業的最新趨勢及影響分析
  • 公司和競爭對手的分類
  • 供應商情況
  • 主要銷售代理商和通路夥伴名單
  • 主要公司市佔率分析（2025 年）
    • F. Hoffmann-La Roche Ltd
    • Abbott
    • Siemens Medical Solutions USA, Inc.
    • QuidelOrtho Corporation
    • DiaSorin SpA
    • Beckman Coulter, Inc.
    • Quest Diagnostics Incorporated
    • Labcorp
    • Thermo Fisher Scientific Inc.
    • Bio-Rad Laboratories, Inc.
Product Code: GVR-4-68040-920-5

U.S. CLIA Endocrine Testing Market Summary

The U.S. CLIA endocrine testing market size was estimated at USD 14.06 billion in 2025 and is projected to reach USD 34.38 billion by 2033, growing at a CAGR of 11.94% from 2026 to 2033. Market growth is supported by the increasing prevalence of chronic and hormonal disorders and the need for high sensitivity and analytical accuracy in hormone detection.

Advancements in automated CLIA platforms are enhancing diagnostic efficiency. Furthermore, regulatory compliance under the Clinical Laboratory Improvement Amendments ensures standardized testing quality, supporting consistent adoption of endocrine testing services in the U.S.

The rising burden of chronic and hormonal disorders is significantly increasing the demand for endocrine testing in the U.S. Conditions such as diabetes, thyroid dysfunction, and polycystic ovary syndrome (PCOS) are becoming more prevalent due to aging populations, sedentary lifestyles, obesity, and environmental factors. According to the report published by the World Health Organization in January 2026, PCOS affects approximately 10-13% of reproductive-age women globally, with nearly 70% of cases remaining undiagnosed, indicating a substantial gap in diagnostic testing. Moreover, the National Center for Biotechnology Information reports that at least 5% of adults in the U.S. are affected by endocrine disorders, including hypothyroidism, osteopenia, and vitamin D deficiency. This growing clinical burden is driving consistent demand for advanced, high-sensitivity endocrine testing across CL0IA-certified laboratories in the U.S.

Advancements in automated chemiluminescence immunoassay (CLIA) platforms are significantly improving the efficiency, scalability, and precision of endocrine testing in the U.S. Modern CLIA analyzers are designed for high-throughput processing, minimal manual intervention, and rapid turnaround times, enabling laboratories to handle large test volumes while reducing operational errors. These systems support automated sample handling, calibration, and result interpretation, which enhances reproducibility and consistency in hormone analysis. For instance, in March 2026, F. Hoffmann-La Roche Ltd. received a CLIA moderate-complexity classification from the U.S. Food and Drug Administration for its Ionify steroid assays integrated with the cobas Mass Spec solution, enabling routine clinical laboratories to perform highly accurate steroid hormone testing through automated, standardized workflows. These advancements are accelerating the adoption of high-throughput, automated endocrine testing solutions across U.S. CLIA-certified laboratories, supporting improved diagnostic efficiency and scalability.

Regulatory compliance under the Clinical Laboratory Improvement Amendments is supporting the growth of the U.S. CLIA endocrine testing industry by ensuring standardized testing quality, accuracy, and reliability across laboratories. These regulations mandate strict quality control, proficiency testing, and personnel standards, reducing diagnostic errors and improving clinical confidence in hormone test results. The classification of tests based on complexity also enables laboratories to expand service offerings while maintaining compliance. This structured framework encourages the adoption of advanced automated testing platforms. It promotes consistency in diagnostic practices, ultimately increasing test volumes and supporting the sustained expansion of endocrine testing services across the U.S.

The growth of large reference laboratories, combined with favorable reimbursement and insurance coverage, is supporting the expansion of the U.S. CLIA endocrine testing market. Major diagnostic laboratories are increasing capacity and adopting automation, enabling centralized testing models with higher throughput and faster turnaround times. This enhances operational efficiency and supports large-scale endocrine testing. In parallel, reimbursement policies in the U.S. encourage the use of diagnostic services by improving affordability and access. Although pricing pressures persist, consistent insurance coverage continues to sustain testing demand, contributing to steady market growth.

U.S. CLIA Endocrine Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. CLIA endocrine testing market report based on product, testing type, and clinical setting:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Kits & Reagents
  • Instruments
  • Testing Type Outlook (Volume, Number of Tests; Revenue, USD Million, 2021 - 2033)
  • Thyroid Testing
    • TSH
    • Free T4 (fT4)
    • T4 (Total)
    • Free T3 (FT3)
    • T3 (Total)
    • Anti-TPO
    • Anti-Tg
    • Thyroglobulin (Tg)
    • T3 Resin Uptake
  • Hormone Testing
    • FSH
    • hCG
    • Testosterone
    • Progesterone
    • Prolactin
    • Estradiol E2
    • Luteinizing Hormone (LH)
    • Sex Hormone-Binding Globulin (SHBG)
    • DHEA-S (dehydroepiandrosterone sulfate)
    • Human growth hormone (HGH)
    • Anti-Mullerian Hormone (AMH)
  • Bone Health
    • Vitamin D
    • Parathyroid hormone (PTH)
    • Serum CTX (Carboxy-terminal collagen crosslinks)
    • NTx (N-telopeptide)
    • Osteocalcin
    • Alkaline phosphatase (ALP)
  • Clinical Setting Outlook (Volume, Number of Tests; Revenue, USD Million, 2021 - 2033)
  • OBGYN office
  • Fertility / IVF Clinics
  • Physician office labs (POLs)
  • Hospital Labs Small (<100 beds)
  • Hospital Labs Large (>500 beds)
  • Others

Table of Contents

Chapter 1. U.S. CLIA Endocrine Testing Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Method
      • 1.1.1.2. Testing Type Segment
      • 1.1.1.3. Clinical Settings Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. U.S. CLIA Endocrine Testing Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product Snapshot
  • 2.3. Testing Type Snapshot
  • 2.4. Clinical Settings Snapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. U.S. CLIA Endocrine Testing Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Increasing prevalence of chronic and hormonal disorders
    • 3.4.2. Need for high sensitivity and analytical accuracy in hormone detection.
    • 3.4.3. Advancements in automated CLIA platforms
    • 3.4.4. Regulatory compliance under the clinical laboratory improvement amendments
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost of advanced CLIA platforms and testing infrastructure
    • 3.5.2. Stringent regulatory and compliance requirements
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. U.S. CLIA Endocrine Testing Market: Product Estimates & Trend Analysis

  • 4.1. U.S. CLIA Endocrine Testing Market: Product Dashboard
  • 4.2. U.S. CLIA Endocrine Testing Market: Product Movement Analysis
  • 4.3. U.S. CLIA Endocrine Testing Market by therapy, Revenue
  • 4.4. Kits & Reagents
    • 4.4.1. Kits & Reagents market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Instruments
    • 4.5.1. Instruments market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. CLIA Endocrine Testing Market, By Testing Type, 2021 - 2033 Value (USD Million), Volume (Number of tests)

  • 5.1. Thyroid Testing market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.1.1. TSH market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.1.2. Free T4 (fT4) market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.1.3. T4 (Total) market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.1.4. Free T3 (FT3) market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.1.5. T3 (Total) market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.1.6. Anti-TPO market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.1.7. Anti-Tg market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.1.8. Thyroglobulin (Tg) market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.1.9. T3 Resin Uptake market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.2. Hormone Testing market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.2.1. FSH market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.2.2. hCG market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.2.3. Testosterone market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.2.4. Progesterone market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.2.5. Prolactin market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.2.6. Estradiol E2 market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.2.7. Luteinizing Hormone (LH) market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.2.8. Sex Hormone-Binding Globulin (SHBG) market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.2.9. DHEA-S (dehydroepiandrosterone sulfate) market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.2.10. Human growth hormone (HGH) market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.2.11. Anti-Mullerian Hormone (AMH) market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3. Bone Health market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.1. Vitamin D market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.2. Parathyroid hormone (PTH) market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.3. Serum CTX (Carboxy-terminal collagen crosslinks) market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.4. NTx (N-telopeptide) market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.5. Osteocalcin market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.6. Alkaline phosphatase (ALP) market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. CLIA Endocrine Testing Market, Clinical Setting by Testing Type, 2021 - 2033 Value (USD Million), Volume (Number of tests)

  • 6.1. U.S. CLIA Endocrine Testing Market: Testing Type, Value (USD Million), Volume (Number of tests) Dashboard
  • 6.2. U.S. CLIA Endocrine Testing Market: Testing Type, Value (USD Million), Volume (Number of tests) Movement Analysis
  • 6.3. U.S. CLIA Endocrine Testing Market by Testing Type, Value (USD Million), Volume (Number of tests)
  • 6.4. OBGYN office
    • 6.4.1. OBGYN office market estimates and forecasts 2021 to 2033 (USD Million) (Number of tests)
  • 6.5. Physician office labs (POLs)
  • 6.6. Physician office labs (POLs) market estimates and forecasts 2021 to 2033 (USD Million) (Number of tests)
  • 6.7. Hospital Labs Small (<100 beds)
    • 6.7.1. Hospital Labs Small (<100 beds) market estimates and forecasts 2021 to 2033 (USD Million)(Number of tests)
  • 6.8. Hospital Labs Medium (100-500 beds)
    • 6.8.1. Hospital Labs Medium (100-500 beds) market estimates and forecasts 2021 to 2033 (USD Million) (Number of tests)
  • 6.9. Hospital Labs Large (>500 beds)
    • 6.9.1. Hospital Labs Large (>500 beds) market estimates and forecasts 2021 to 2033 (USD Million) (Number of tests)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
  • 7.4. List of key distributors and channel partners
  • 7.5. Key customers
  • 7.6. Key company market share analysis, 2025
    • 7.6.1. F. Hoffmann-La Roche Ltd
      • 7.6.1.1. Company overview
      • 7.6.1.2. Financial performance
      • 7.6.1.3. Product benchmarking
      • 7.6.1.4. Strategic initiatives
    • 7.6.2. Abbott
      • 7.6.2.1. Company overview
      • 7.6.2.2. Financial performance
      • 7.6.2.3. Product benchmarking
      • 7.6.2.4. Strategic initiatives
    • 7.6.3. Siemens Medical Solutions USA, Inc.
      • 7.6.3.1. Company overview
      • 7.6.3.2. Financial performance
      • 7.6.3.3. Product benchmarking
      • 7.6.3.4. Strategic initiatives
    • 7.6.4. QuidelOrtho Corporation
      • 7.6.4.1. Company overview
      • 7.6.4.2. Financial performance
      • 7.6.4.3. Product benchmarking
      • 7.6.4.4. Strategic initiatives
    • 7.6.5. DiaSorin S.p.A.
      • 7.6.5.1. Company overview
      • 7.6.5.2. Financial performance
      • 7.6.5.3. Product benchmarking
      • 7.6.5.4. Strategic initiatives
    • 7.6.6. Beckman Coulter, Inc.
      • 7.6.6.1. Company overview
      • 7.6.6.2. Financial performance
      • 7.6.6.3. Product benchmarking
      • 7.6.6.4. Strategic initiatives
    • 7.6.7. Quest Diagnostics Incorporated
      • 7.6.7.1. Company overview
      • 7.6.7.2. Financial performance
      • 7.6.7.3. Product benchmarking
      • 7.6.7.4. Strategic initiatives
    • 7.6.8. Labcorp
      • 7.6.8.1. Company overview
      • 7.6.8.2. Financial performance
      • 7.6.8.3. Product benchmarking
      • 7.6.8.4. Strategic initiatives
    • 7.6.9. Thermo Fisher Scientific Inc.
      • 7.6.9.1. Company overview
      • 7.6.9.2. Financial performance
      • 7.6.9.3. Product benchmarking
      • 7.6.9.4. Strategic initiatives
    • 7.6.10. Bio-Rad Laboratories, Inc.
      • 7.6.10.1. Company overview
      • 7.6.10.2. Financial performance
      • 7.6.10.3. Product benchmarking
      • 7.6.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. CLIA Endocrine Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 4 U.S. CLIA Endocrine Testing Market, By Testing Type, Volume (Number of tests), 2021 - 2033 (USD Million)
  • Table 5 U.S. CLIA Endocrine Testing Market, By Clinical Setting, Volume (Number of tests), 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. CLIA endocrine testing market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment.
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. CLIA endocrine testing market snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook.
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. CLIA endocrine testing market: Product movement analysis
  • Fig. 14 U.S. CLIA endocrine testing market: Product outlook and key takeaways
  • Fig. 15 Kits & reagents market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 16 Instruments market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 17 U.S. CLIA endocrine testing market: clinical setting, volume (number of tests) movement analysis
  • Fig. 18 U.S. CLIA endocrine testing market: clinical setting, volume (number of tests) outlook and key takeaways
  • Fig. 19 Parenteral market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 20 OBGYN office market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 21 Fertility / IVF clinics market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 22 Physician office labs (POLs) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 23 Hospital labs medium (100-500 beds) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 24 Hospital Labs Large (>500 beds) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 25 Others market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 26 U.S. CLIA endocrine testing market: testing type, volume (number of tests) movement analysis
  • Fig. 27 U.S. CLIA endocrine testing market: testing type, volume (number of tests) outlook and key takeaways
  • Fig. 28 Thyroid Testing market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 29 TSH market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 30 Free T4 (fT4) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 31 T4 (Total) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 32 Free T3 (FT3) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 33 T3 (Total) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 34 Anti-TPO market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 35 Anti-Tg market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 36 Thyroglobulin (Tg) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 37 T3 Resin Uptake market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 38 Hormone Testing market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 39 FSH market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 40 Hcg market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 41 Testosterone market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 42 Progesterone market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 43 Prolactin market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 44 Estradiol E2 market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 45 Luteinizing Hormone (LH) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 46 Sex Hormone-Binding Globulin (SHBG) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 47 DHEA-S (dehydroepiandrosterone sulfate) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 48 Human growth hormone (HGH) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 49 Anti-Mullerian Hormone (AMH) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 50 Bone Health market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 51 Vitamin D market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 52 Parathyroid hormone (PTH) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 53 Serum CTX (Carboxy-terminal collagen crosslinks) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 54 Market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 55 NTx (N-telopeptide) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 56 Osteocalcin market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 57 Alkaline phosphatase (ALP) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
  • Fig. 58 U.S. CLIA endocrine testing market: Product movement analysis
  • Fig. 59 U.S. CLIA endocrine testing market: Product outlook and key takeaways
  • Fig. 60 U.S. CLIA endocrine testing market: Clinical settings movement analysis
  • Fig. 61 U.S. CLIA endocrine testing market: Clinical settings outlook and key takeaways
  • Fig. 62 U.S. CLIA endocrine testing market: Testing type movement analysis
  • Fig. 63 U.S. CLIA endocrine testing market: Testing type outlook and key takeaways
  • Fig. 64 Market share of key market players- U.S. CLIA endocrine testing market